Omniab (NASDAQ: OABI) reported Q4 2023 earnings per share (EPS) of -$0.14, up 255.56% year over year. Total Omniab earnings for the quarter were -$14.05 million. In the same quarter last year, Omniab's earnings per share (EPS) was $0.09.
As of Q2 2024, Omniab's earnings has grown year over year. Omniab's earnings in the past year totalled -$50.62 million.
What was OABI's revenue last quarter?
Omniab (NASDAQ: OABI) reported Q4 2023 revenue of $4.82 million up 86.36% year over year. In the same quarter last year, Omniab's revenue was $35.35 million.
What was OABI's revenue growth in the past year?
As of Q2 2024, Omniab's revenue has grown -42.17% year over year. This is 193.63 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Omniab's revenue in the past year totalled $34.16 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.